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The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 Statement was devel-
oped to provide guidance for inclusion of key methodological components in clinical trial protocols. However,
these standards do not include guidance specific to pathology input in clinical trials. This systematic review
aims to synthesise existing recommendations specific to pathology practice in clinical trials for implementa-
tion in trial protocol design. Articles were identified from database searches and deemed eligible for inclusion
if they contained: (1) guidance and/or a checklist, which was (2) pathology-related, with (3) content relevant
to clinical trial protocols or could influence a clinical trial protocol design from a pathology perspective and
(4) were published in 1996 or later. The quality of individual papers was assessed using the AGREE-GRS
(Appraisal of Guidelines for REsearch & Evaluation – Global Rating Scale) tool, and the confidence in cumu-
lative evidence was evaluated using the GRADE-CERQual (Grading of Recommendations Assessment, Develop-
ment and Evaluation–Confidence in Evidence from Reviews of Qualitative research) approach. Extracted
recommendations were synthesised using the best fit framework method, which includes thematic analysis
followed by a meta-aggregative approach to synthesis within the framework. Of the 10 184 records screened
and 199 full-text articles reviewed, only 40 guidance resources met the eligibility criteria for inclusion. Rec-
ommendations extracted from 22 guidance documents were generalisable enough for data synthesis. Seven
recommendation statements were synthesised as follows: (1) multidisciplinary collaboration in trial design
with early involvement of pathologists, particularly with respect to the use of biospecimens and associated
biomarker/analytical assays and in the evaluation of pathology-related parameters; (2) funding and training
for personnel undertaking trial work; (3) selection of an accredited laboratory with suitable facilities to
undertake scheduled work; (4) quality assurance of pathology-related parameters; (5) transparent reporting
of pathology-related parameters; (6) policies regarding informatics and tracking biospecimens across trial
sites; and (7) informed consent for specimen collection and retention for future research.
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Introduction
Randomised controlled trials are considered the ‘gold
standard’ in medical research for comparing the safety
and effectiveness of novel interventions as they mini-
mise bias compared to other empirical study designs,
thus delivering a high level of evidence [1,2]. The con-
fidence in the quality of evidence drawn from the con-
clusions of clinical trials is ultimately only as good as
the robustness of the study design and methodology,
which encompasses the quality assurance of detailed
processes involved in the delivery of the trial [2,3].
Poorly planned clinical trials result in misleading find-
ings from suboptimal trial execution and analysis, thus
wasting resources and potentially harming patients [4].
Such issues can be mitigated by methodologically rig-
orous clinical trial protocols to facilitate the design,
conduct, analysis, and reporting of reliable clinical tri-
als [3–5]. For this reason, the SPIRIT (Standard Proto-
col Items: Recommendations for Interventional Trials)
2013 Statement was developed to provide standardised
guidance for inclusion of key methodological compo-
nents in clinical trial protocols [6]. However, these
standards do not include guidance specific to pathol-
ogy input in clinical trials.
To attain methodological rigour in trials, there is
increasing recognition of the need for pathologists to
be involved early in trial planning and design [7–10].
Current literature contains a considerable number of
reviews and perspective papers offering opinions from
various pathologists and biomedical scientists on differ-
ent specific aspects of the laboratory workflow that
could improve clinical trial quality [7–42]. However,
there is no single comprehensive guidance document
covering all aspects of pathology workflow feeding into
various stages of the clinical trial process. Furthermore,
trialists writing protocols typically have a limited
understanding of the role of the laboratory and patholo-
gist in their studies and may overlook key issues that
need to be addressed during the design phase.
Aims and objectives
This systematic review aims to synthesise existing
guidance and recommendations for pathology practice
in clinical trials for implementation in trial protocol
design.
Based on recent systematic review typology recom-
mendations by Munn et al [43] from the Joanna Briggs
Institute (JBI), this is a systematic review of expert
opinion. The review question was therefore developed
based on the recommended PICo (Population, phenom-
ena of Interest, Context) framework, as follows:
• P (Population): individuals involved in the design,
conduct, and analysis of clinical trials requiring
pathology input.
• I (phenomena of Interest): recommendations or
guidelines specific to pathology input (within the
‘context’ below).
• Co (Context): the entire clinical trial process, from
the design and conduct of the trial to the analysis
and dissemination of trial findings.
Review question: What recommendations are avail-




The protocol was prospectively registered on the Open
Science Framework online repository (Registration DOI:
https://doi.org/10.17605/osf.io/jeqtx) [44]. This review
was reported in accordance with the 2009 PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement [45].
Eligibility criteria
Resources were deemed eligible for inclusion if they
contained: (1) guidance (in the form of guidelines or
expert recommendations) and/or a checklist, which is
(2) pathology-related, with (3) content relevant to clini-
cal trial protocols or could influence a clinical trial pro-
tocol design from a pathology perspective. In addition,
the year of publication was restricted to include
resources published in 1996 or later, after the publica-
tion of the CONSORT (Consolidated Standards Of
Reporting Trials) Statement guidelines [46]. There were
no other restrictions by language or publication type.
Information sources and search strategy
The search strategy was devised by initially scoping
the literature on MEDLINE and EMBASE via the
Ovid platform, as well as an internet search on Google
Scholar to identify a comprehensive set of relevant
search terms. The full search strategies for all data-
bases and web searches are available in the review
protocol [44]. Free-text terms such as ‘(histolo*; OR
patholo*)’ AND ‘(checklist; OR guideline; OR recom-
mendation)’ AND ‘(clinical trial; OR protocol)’, along
with equivalent controlled vocabulary terms, were
used in the search of the MEDLINE (Ovid), EMBASE
(Ovid), and Cochrane Library databases. Additional
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search terms such as ‘biomarker*’, ‘molecular dia-
gnos*’, ‘practice guid*’, and ‘study design’ were also
applied across the MEDLINE and EMBASE data-
bases. Web searches on Google and Google Scholar
were performed using the advanced search function
with the keywords ‘(Pathology; OR Histology; OR
Biomarkers)’ AND ‘(Guideline; OR Checklist)’ AND
‘Clinical trial’. Only the first three pages (30 results)
from each internet search were screened as lower-
ranked results are less relevant to the search query
[47]. The databases and search engines were searched
from 1 January 1996 to 13 January 2020. Besides the
year of publication, no other limitations (such as lan-
guage restrictions or restrictions by publication status)
were placed on the searches.
Selection of guidance resources
All citations were imported into Mendeley Desktop
software (Elsevier, London, UK; Version 1.19.5/
2019). The titles and abstracts of the records were
screened by two reviewers; SJL screened all the
records, and TJK and MR acted as second reviewers.
Inter-rater agreement between the two reviewers was
measured using Fleiss’ kappa (κ), and the strength of
agreement was interpreted according to Landis and
Koch [48]. In cases where an abstract was not avail-
able, the full text of the article was retrieved.
Resources that both reviewers selected for inclusion
were subjected to full-text review, while any disagree-
ments were arbitrated by a third reviewer (TJK or
MR). Two reviewers independently reviewed the full
texts; any disagreements were discussed with a third
reviewer and resolved by consensus. Resources not
meeting the inclusion criteria upon review of full texts
were excluded with reasons provided.
Quality assessment of guidance resources
Each eligible guidance resource was appraised by two
reviewers independently using the AGREE-GRS qual-
ity assessment instrument [49]. The final scores for each
domain of the AGREE-GRS tool were calculated based
on the method recommended in the AGREE II User’s
Manual [50]. Scores of 33% and below for each domain
were considered to be of low quality, scores between
34% and 66% were considered to be of moderate qual-
ity, and scores of 67% and more were considered to be
of high quality. Guidance resources were not excluded
based on the quality scores. The scores were used to
compare the variation in methodological quality across
guidance resources, which were then categorised as
low, moderate, and high quality based on the AGREE-
GRS scores. This was used to inform judgement on the
level of confidence in the evidence contributing to the
final recommendation statements using principles from
the GRADE-CERQual (Grading of Recommendations
Assessment, Development and Evaluation–Confidence
in Evidence from Reviews of Qualitative research)
approach [51–56].
Data extraction and data items
Using best practice guidance from the JBI Manual for
Evidence Synthesis [57], a pre-piloted digital data
extraction form was customised in Excel, which was
adapted from the JBI ‘text and opinion data extraction
tool’ [58] to incorporate data fields specific to system-
atic reviews of textual opinion-based evidence. The
following specific data items were extracted from each
resource:
• population – target audience for which guidance is
developed;
• context within trial – areas of pathology input within
clinical trial;
• phenomena of interest – variables associated with
pathology-specific trial guidance (guidance develop-
ment methodology, organisational and geographical
representation contributing to guidance development,
reference to clinical research regulatory authority, clin-
ical specialty focus, presence of a pathology-specific
trial protocol checklist);
• verbatim extracts of guidance statements; and
• interpretation of guidance statements; classifying guid-
ance statements as ‘explicit’ or ‘implicit’ (explicit –
‘distinctly expressing all that is meant; leaving nothing
merely implied or suggested’; implicit – ‘suggested or
understood but not directly expressed’) [59].
Data from each selected resource were indepen-
dently extracted by two reviewers onto the data extrac-
tion form, followed by checks for consistency. Any
discrepancies were first discussed between the two
reviewers, and any disagreements were resolved by a
third reviewer.
Data synthesis and analysis
We used the best fit framework synthesis method
[60–62], which incorporates all elements of the JBI
meta-aggregation approach [63,64], for synthesis and
analysis of descriptive qualitative data. The best fit
framework synthesis method incorporates techniques
from both the framework synthesis and thematic anal-
ysis methods. We followed the five stages of this
method, which involved ‘familiarisation’ with the
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literature to select an appropriate a priori framework
(the SPIRIT 2013 Statement [6] was used as the a
priori framework). This framework was applied to the
‘indexing’, ‘charting’, and ‘mapping and interpreta-
tion’ of extracted guidance statements in the data
extraction, synthesis, and analysis stages of the review,
respectively.
Results
Selection of guidance resources
The database searches identified 12 403 records: 2706
from MEDLINE (Ovid), 5264 from EMBASE (Ovid),
and 4433 from Cochrane Library. The web searches
identified another 56 unique records. The supplemen-
tary search of reference lists yielded an additional
48 unique records, of which 12 full-text articles were
eligible for inclusion. No grey literature was identified.
The titles and abstracts of 10 184 records were
screened after de-duplication. A total of 9985 records
were excluded by screening titles and abstracts
(κ = 0.76, substantial agreement). From the 199 full-
text articles retrieved and assessed for eligibility,
40 articles were included in the review (κ = 0.65, sub-
stantial agreement). There were no foreign language
articles. The other 159 full-text articles were excluded
with reasons stated in Figure 1.
Characteristics of guidance resources
Of the 40 guidance resources included [7,9,11–32,34–
42,65–71], around half (n = 21, 53%) offered recom-
mendations pertaining to all aspects of pathology input
within clinical trials (patient selection, risk stratifica-
tion, and outcome assessment) [7,9,11,13,17,20,26–
30,35,36,38,41,42,65,67–70]. Seven (17%) of the
included guidance resources contained explicit recom-
mendations [7,18,31,39,41,66,71], 24 (60%) contained
implicit recommendations [9,11–16,19,22–25,27–30,
34–37,42,67,69,70], and the remaining 9 (23%)
offered a combination of explicit and implicit recom-
mendations [17,20,21,26,32,38,40,65,68]. Only four
guidance resources had a pathology-specific trial pro-
tocol checklist [17,18,32,34]. A third of the guidance
resources (n = 13) referenced one or more clinical
research regulatory authority [9,11,18,22,25,26,32,38,
40,65,67–69]. Detailed characteristics of individual
guidance resources are provided in supplementary mate-
rial, Table S1.
Quality assessment
The quality scores for each AGREE-GRS domain (out
of 100%) for individual guidance resources are avail-
able in supplementary material, Table S2. All guidance
resources were considered to be highly relevant and
applicable to clinical trial practice (Figure 2). The
majority of the guidance resources was assessed to
have high quality (AGREE-GRS score of >67%).
However, the quality was considered to be lower
(AGREE-GRS score of <33%) in the AGREE-GRS
domain of ‘completeness of reporting’, subsequently
mapping to the GRADE-CERQual domain of ‘ade-
quacy of data’.
Heterogeneity across guidance resources
Sources of heterogeneity that could contribute to bias
across guidance resources are listed in Table 1. The
majority (58%) of the included guidance resources
was discussion papers (including perspectives or opin-
ion papers), while the remainder consisted of a mixture
of literature review, primary research papers, letters to
editors, regulatory authority guidance documents, and
methodology papers. The majority of the resources
(73%) were published in the last decade, whereas only
two (5%) were published between 1996 and 2005; the
remaining were published between 2006 and 2010. In
terms of the guidance development process, nearly half
(45%) of the resources had employed a rigorous devel-
opment methodology involving a formal working
group at a national or international level, while
15 (38%) did not report a formal methodology. The
majority of these 15 that did not report a formal meth-
odology (n = 11) was based on the opinions, perspec-
tives, and experiences of a selected group of authors.
Nearly half of the guidance resources (45%) were rec-
ommendations developed by the United States and/or
Canada, whereas only a quarter were developed by the
United Kingdom (n = 5) and other countries within
Europe (n = 5). Only 10 resources (25%) included rec-
ommendations developed from an international repre-
sentation of experts.
Results of individual guidance resources
The verbatim extracts of recommendation statements
from each individual guidance resource, mapped onto
the a priori framework (the SPIRIT 2013 Statement)
[6], followed by its associated interpretation and ‘char-
ting’ are available on the Open Science Framework
online repository [72]. During the charting stage, the
recommendation statements from the individual guid-
ance resources were coded into themes that best
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describe the nature and type of recommendations offer-
ing best practice guidance at various stages of the clini-
cal trial process. The charting process revealed that the
themes could be broadly categorised according to
stages of the clinical trial process, namely, pre-analyti-
cal, analytical, and post-analytical phases, as well as
across all phases of the trial. Table 2 shows the fre-
quency and distribution of resources offering guidance
for each identified theme.
The recommendation statements categorised according
to recurring themes form the basis of synthesised recom-
mendations. Other guidance resources offering standalone
recommendations do not contribute to any recurring
themes and are therefore not generalisable enough for
synthesis; these are discussed below.
Five of the guidance resources contain recommenda-
tions specific only to certain types of clinical trials. These
include best practice guidance for specific laboratory
Figure 1. PRISMA flow diagram of selection process of guidance resources.
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techniques such as tissue microarray construction and
evaluation [42], consideration of laboratory technical
parameters in omics-based clinical trials [26], and the
technical aspects of biomarker development [16] and bio-
marker integration [18,25] in early-phase clinical trials.
Eleven of the guidance resources offer recommenda-
tions focused on the pre-analytical and analytical
phases of clinical trials specific to a clinical specialty,
such as breast cancer [12,20,21,31,40], non-small cell
lung cancer [34], paediatric neuroblastoma [37], paedi-
atric rheumatology [36], prostate cancer [14], and lym-
phoma [15,23]. Details of these disease-specific
recommendations are shown in supplementary mate-
rial, Table S3.
The guidance documents from the European Medi-
cines Agency [65] and the Medicine and Healthcare
products Regulatory Agency [68] stipulate the mini-
mum regulatory standards to which all laboratory
supporting clinical trial work should adhere. As meet-
ing these standards is a legal requirement, these two
resources have not been included in recommendation
synthesis.
Synthesis of recommendations
Best practice recommendation statements that contrib-
uted to the recurring themes were gathered and
synthesised from 22 of the guidance resources
[7,9,11,13,17,19,22,24,27–30,32,35,38,39,41,66,67,69–71]
using the JBI meta-aggregation approach (see
supplementary material, Table S4). The GRADE-
CERQual evidence profile (see supplementary material,
Table S5) shows the CERQual assessment details, with
reasons for reaching the judgements, for each of the
four GRADE-CERQual components. The synthesised
pathology-specific recommendations at different stages
of the clinical trial process, along with the overall confi-
dence in each synthesised statement, are as follows:
Pre-analytical phase
Recommendation 1 (R1): The responsibilities and level
of involvement in clinical trial work should be agreed
upon among all multidisciplinary collaborators and for-
mally documented prior to trial opening. Input from
pathologists and other relevant personnel with technical
laboratory and statistical expertise and experience
should be sought during the development of trial proto-
col, trial design, and implementation, in particular for
justifying the use of biospecimens and/or a specific bio-
marker and associated analytical assays in the clinical
trial, as well as reaching a consensus on pre-specified
definitions of pathology-related parameters when inter-
preting findings for trial inclusion or risk stratification.
(Moderate confidence).
Recommendation 2 (R2): All personnel undertaking
any aspect of clinical trial work should have proper
accreditation and sufficient funding and training
corresponding to their involvement and role in the
clinical trial. (High confidence).
Figure 2. Proportion of guidance resources showing low, moderate, and high quality across AGREE-GRS domains.
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Recommendation 3 (R3): The laboratory site
selected to carry out trial work should have:
i. appropriate accreditation, with practices of labora-
tory management and operations complying with
standards of regular external quality assurance
schemes;
ii. capacity to adhere to trial-specific standard operat-
ing procedures in the testing platforms and prepa-
ration and storage of sample; and
iii. suitable facilities required for the trial (e.g.
accredited digital pathology platforms). (Moderate
confidence).
Analytical phase
Recommendation 4 (R4): Plans to ensure the complete-
ness and accuracy of pathology-related data sets in
clinical trials should be clearly documented and should
address the following:
i. a system for prospective rapid real-time central
pathology review or double reporting with consen-
sus to achieve uniformity in diagnosis;
ii. use of standardised digital pathology platforms
where appropriate;
iii. data quality review by a trained pathology quality
manager or review committee to ensure adherence
to standardised pathology examination and inter-
pretation procedures; and
iv. regular analytical audits of internal testing platforms
and assay performance testing and validation of
inter-pathologist reproducibility and inter-laboratory
repeatability analysis. (High confidence).
Post-analytical phase
Recommendation 5 (R5): The pathology-relevant aspects
of clinical trials should be transparently reported
according to the BRISQ (Biospecimen Reporting for
Improved Study Quality) checklist and REMARK
(REporting recommendations for tumour MARKer
prognostic studies) criteria, where appropriate, to include
specific details relevant to biospecimen procurement,
type, anatomical site, and associated patients’ clinical
details, as well as protocols for tissue preparation, pres-
ervation, and biomarker staining parameters. These stan-
dard operating procedures for the management of
biospecimens during the clinical trial should be regis-
tered on a publicly accessible database, with digital loca-
tion cited in the research publication. (Low confidence).
Across all trial phases
Recommendation 6 (R6): Laboratories and biorepositories
should have policies and procedures with secure informat-
ics systems in place to minimise risks of harm to
participants and to protect the confidentiality and data
of participants, including anonymising collected bio-
specimens, tracking the movement of biospecimens within
and across sites, and ensuring consent for biospecimen
retention is valid prior to storage. (Moderate confidence).
Recommendation 7 (R7): Patient information sheets
and consent forms should be reviewed by pathologists
and should include information pertaining to the ratio-
nale of the use of biospecimen within the context of
the clinical trial; the risks and benefits involved; how
data will be analysed, stored, transferred between insti-
tutions, and shared with their healthcare providers; the
details of biospecimen collection (type, frequency,
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volume, or size of sample); and specimen retention
policies for future research. In studies involving geno-
mics or genetics, participants should specifically be
counselled on the implications of a positive result on
themselves and their relatives. (Moderate confidence).
Discussion
Applicability of synthesised findings to clinical trial
practice
The findings of this review yielded seven synthesised
recommendation statements, covering the pre-analytical,
analytical, and post-analytical phases of clinical trials, as
well as guidance pertaining to biospecimen ethics and
informed consent documentation, which spans across all
phases of the clinical trial process. The GRADE-
CERQual Summary of Qualitative Findings (see supple-
mentary material, Table S6) shows a summary of the
synthesised recommendations and their respective overall
quality. It also shows the applicability of each of the
seven synthesised recommendation statements to particu-
lar aspects of the clinical trial process and the relevance
of each recommendation to different groups of key clini-
cal trial stakeholders, as well as the implications of each
recommendation on potentially changing clinical trial
practice in trial protocol development and trial reporting,






Accreditation and training of pathologists 8 20 [9,11,13,25,38,65,68,69]
Accreditation and training of laboratory staff 4 10 [9,13,65,68]
Statistical and technical laboratory expertise for pathology-based
parameters
8 20 [11,16–18,26,32,42,69]
General laboratory systems and facilities
Laboratory accreditation 10 25 [7,11,13,18,25,28,38,65,68,69]
Assay validation and performance testing 4 10 [13,17,18,25]
Standardisation of laboratory processes (including standard operating
procedures)
4 10 [11,13,65,68]
Rationale for pathology-specific criteria
Use of biospecimens, specific biomarker, or associated analytical assay 8 20 [17,18,22,24,25,32,67,71]
Inclusion criteria or risk stratification 3 7.5 [22,25,32]
Outcome measurement 3 7.5 [22,32,41]
Biospecimens
Standardisation of sample collection and handling procedures 7 17.5 [7,17,19,25,28,67,70]
Sample storage conditions 5 12.5 [19,28,67,68,70]
Sample transport conditions across sites 7 17.5 [17,19,25,28,67,68,70]
Biobank facilities 4 10 [19,28,67,70]
Disease-specific pre-analytical sampling and processing methods (see
supplementary material, Table S3)
4 10 [20,21,34,36]
Multidisciplinary collaboration among all parties involved in trial 10 25 [7,9,11,17,18,24–26,65,67]
Funding of materials, laboratory staff, and pathologists 4 10 [11,18,32,38]
Analytical phase Microscopic assessment methods
Use of artificial intelligence for microscopic analysis 2 5 [29,38]
Central pathology review 3 7.5 [11,35,66]
Histopathology reporting 2 5 [7,68]
Disease-specific analytical methods (see supplementary material, Table S3) 8 20 [12,14,15,23,31,34,37,40]
Auditing and data validation 8 20 [11,13,18,30,35,38,66,68]
Post-analytical phase Dissemination of results
Data sharing 3 7.5 [19,28,70]
Transparent reporting 3 7.5 [27,28,70]
Across all trial phases Data monitoring and validation 5 12.5 [18,30,42,65,68]
Informed consent materials and supporting documentation to be given to
participants
8 20 [11,17,18,24,39,41,67,69]
Confidentiality and data protection 5 12.5 [18,25,41,67,68]
Ethics surrounding biospecimens collection, handling, storage, and
transport
4 10 [24,39,41,67]
Ethics surrounding genetic testing and data sharing 2 5 [25,67]
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within the context of the SPIRIT Statement [6] and
CONSORT Statement [73] checklist items.
Strengths and limitations
This systematic review has been transparently reported
according to the PRISMA 2009 Statement. Selection
bias of resources was minimised by having no restric-
tions placed on language and publication type and by
two reviewers independently selecting the studies for
inclusion. Publication bias was mitigated by searching
several databases and the web. Furthermore, this sys-
tematic review has been conducted in accordance with
the international best practice guidance provided by
the JBI Manual for Evidence Synthesis [57] for this
type of reviews of text and opinion, except for the use
of alternative assessment tools for appraising the qual-
ity of individual studies (AGREE-GRS used instead of
‘JBI-Qualitative Critical Appraisal Checklist’) and in
establishing confidence in the synthesised evidence
(GRADE-CERQual used instead of the ConQual
approach). The AGREE-GRS tool was used because
its checklist questions are more suitable and appropri-
ate for use to evaluate the quality of the nature of con-
tent (recommendations and guidelines) presented in the
papers within this systematic review compared to that
of the JBI-Qualitative Critical Appraisal Checklist [57].
The GRADE-CERQual approach to establishing confi-
dence was subsequently adopted as the domains of
AGREE-GRS map better onto the GRADE-CERQual
assessment domains than the ConQual assessment
domains. During the data synthesis process of this sys-
tematic review, the formulation of recommendation
statements and the quality assessment of cumulative
evidence using the CERQual approach were determined
through the consensus of three reviewers.
Individual guidance resources were found to be het-
erogeneous. The majority of publications were in the
last decade, suggesting relevance to current pathology-
related practices within clinical trials, such as the use of
digital pathology in data quality assurance and central
pathology review. However, more than half of the
resources included were discussion papers in the form
of opinion papers and perspective papers, which is the
main limitation to this review in terms of status on the
evidence hierarchy. In fact, most of the synthesised rec-
ommendations with overall confidence downgraded to
‘moderate’ were due to ‘moderate methodological limi-
tations’ on the CERQual assessment as a result of
incomplete documentation of the guideline develop-
ment process within the working groups that published
the perspective papers. Furthermore, the preponderance
of publications with organisational representation in the
Western countries, particularly in the North American
countries, may introduce bias and result in synthesised
recommendations that are not generalisable to trials
conducted in other geographical locations.
Suggestions for future guidance developments
Evidence from this systematic review suggests that the
current literature contains recommendations addressing
most aspects of pathology input into clinical trials.
However, it has not kept up with domains within
pathology that have evolved with recent rapid advance-
ment in technologies used for developing personalised
medicine, which have revolutionised conventional
diagnostic pathology.
There is scope for future developments in pathology-
specific guidance into clinical trials in terms of transparent
reporting of technology-dependent pathology parameters,
particularly pertaining to the use of standardised digital
platforms for histopathological assessment, as well as
techniques for biomarker analysis in the molecular classi-
fication of diseases. Recommendations for genomic pro-
filing methods used in molecular diagnostics, which have
clinical implications for treatment, disease monitoring,
and prognostication, are also currently lacking. These
gaps in the literature can be effectively addressed by
appropriate guideline development initiatives [74].
Conclusions
This systematic review to synthesise pathology-specific
recommendations within clinical trials is the first of its
kind. The findings will inform an international effort to
develop a pathology extension of the SPIRIT Statement
[6], called SPIRIT-Path [74], using the Delphi consen-
sus method involving stakeholders from diverse back-
grounds. Implementation of pathology-specific best
practice recommendations into clinical trial protocols
will enhance the methodological and scientific rigour
of trial delivery, improving the reliability of evidence,
and translating into rational healthcare improvements
for the benefit of patients worldwide.
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